MedTrace Logo

Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer

NCT00174863 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2008-12-23

No results posted yet for this study

Summary

To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor response, survival , safety,Tumor-related symptoms deterioration Quality of Life, PK analysis as secondary objectives

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

SR31747A

Sponsors & Collaborators

Principal Investigators

  • B. TOMBAL, MD · UCL St Luc, Bruxelles BELGIUM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • Australia
  • Belgium
  • Canada
  • Chile
  • Czechia
  • France
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174863 on ClinicalTrials.gov